Accrol Group Holdings plc, the UK's leading independent tissue converter, has reported a strong performance in the first half of the financial year ending October 2023. The company experienced continued volume growth and saw its margins return to pre-pandemic levels quicker than expected. As a result, the Board now expects Adjusted EBITDA for the full year to be at least £21 million. Adjusted net debt as of October 31, 2023, was £25.5 million, down from £30.5 million in the same period last year, and the Board anticipates that adjusted net debt will be close to 1x EBITDA by the end of the financial year. Accrol Group Holdings plc is well positioned to deliver further growth, building on its strong market position and customer base. CEO Gareth Jenkins attributed the company's success to its quality and value products, strong relationships with retailers, and robust supply model.